News >

Patel Provides Perspective on Immunotherapy Developments in NSCLC

Caroline Seymour
Published: Friday, May 25, 2018

Sandip P. Patel, MD

Sandip P. Patel, MD
Immunotherapy’s introduction into the field of non–small cell lung cancer has revolutionized the treatment landscape, most recently following the phase III results of clinical trials such as PACIFIC and KEYNOTE-189, said Sandip P. Patel, MD. Yet, clinicians are working to refine existing and emerging immunologic agents.

State of the Science Summit™ on Non–Small Cell Lung Cancer, Patel, a medical oncologist and assistant professor of medicine at the University of California, San Diego, discussed existing and emerging immunotherapy approaches for patients with locally advanced and metastatic NSCLC.

OncLive: Please provide an overview of your presentation.

Patel: Cancer immunotherapy has revolutionized a variety of different cancers, including NSCLC. There is a wealth of options for our patients. Historically, these options had been chemotherapy. In the age of immunotherapy, including anti–PD-1 agents, we see a variety of different therapeutics in different disease stages.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x